查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1926795

醫藥溫控包裝市場：依包裝類型、溫度範圍、運輸方式、隔熱材料、應用和最終用戶分類－2026-2032年全球預測

Temperature Controlled Package for Pharmaceutical Market by Packaging Type, Temperature Range, Shipping Mode, Insulation Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，醫藥溫控包裝市場規模將達到 42 億美元，到 2026 年將成長至 43.7 億美元，到 2032 年將達到 60 億美元，複合年成長率為 5.23%。

關鍵市場統計數據
基準年 2025 42億美元
預計年份：2026年 43.7億美元
預測年份 2032 60億美元
複合年成長率 (%) 5.23%

一份全面說明，闡述溫控包裝在整個醫藥供應鏈中的戰略作用：熱完整性、可追溯性和操作適用性

隨著複雜生物製藥和溫度敏感治療方法的激增，藥品低溫運輸已成為現代醫療物流的關鍵組成部分。溫控包裝的完整性不再是後勤部門事務，而是維持產品療效、支持合規性以及在全球分銷網路中保護商業性價值的戰略要素。本文概述了影響包裝選擇、合格和實施的技術、營運和監管因素，從而對市場格局進行了分析。

數位化、混合熱處理技術、永續性要求和更高的驗證標準正在重新定義藥品低溫運輸包裝方案。

溫控藥品包裝領域正經歷一場變革性的轉變，重塑採購、設計和監管方式。數位化和互聯感測器實現了連續的溫度和衝擊監測，使認證流程從逐批次抽查轉變為持續檢驗模式，從而顯著降低了風險。同時，合格和被動式技術的整合催生了混合解決方案，將相變材料與電子控制冷卻相結合，以滿足先進生物製藥日益嚴格的溫度控制要求。

評估2025年美國關稅調整對營運和採購的綜合影響，以及這些影響對供應鏈韌性和包裝策略調整的影響

2025年美國政策變遷和關稅措施正在對全球供應鏈產生累積效應，影響籌資策略、運輸方式選擇和包裝經濟效益。關稅帶來的成本壓力促使許多相關人員重新評估其供應商結構，並加速關鍵包裝組件多元化，減少對單一海外製造來源的依賴。這種轉變對前置作業時間、合格要求和庫存策略等下游環節產生影響，因為企業需要尋求更具韌性的方案來應對成本波動，同時維持產品品質。

全面的細分分析揭示了包裝類型、溫度曲線、應用案例、最終用戶需求、運輸方式和隔熱材料選擇如何驅動差異化策略。

有效的市場區隔分析能夠揭示創新和投資能帶來最大回報的領域。要理解這個市場需要從多個交織的觀點。基於包裝類型的市場區隔可以將包裝分為主動式和被動式。主動式解決方案包括電冷卻器、相變材料和冷凍裝置，而被動式解決方案包括乾冰、發泡隔熱材料和冰袋。每種方案都有不同的檢驗要求、能耗和可重複使用性，這些都會影響其在特定貨物上的選擇。基於溫度範圍的分類可以將運輸分為常溫運輸、冷凍運輸和冷藏運輸，從而產生不同的熱性能標準、認證計劃和監控要求，這些要求必須與貨物穩定性要求相一致。

區域差異和市場動態（美洲、歐洲、中東和非洲、亞太地區）會影響包裝材料的選擇、檢驗優先順序和分銷模式。

區域趨勢影響著溫控包裝的規格、採購和運營，地域差異體現在法規結構、基礎設施成熟度和物流網路等方面。在美洲，先進的低溫運輸基礎設施以及對生物製藥和特殊治療藥物的高需求，推動了先進主動式系統和整合監測解決方案的應用，區域中心則成為合格測試和創新的中心。美洲內部的跨境貿易也影響庫存佈局和分銷模式，迫使跨國公司調整其包裝策略，以符合監管要求和商業流通。

成熟製造商、材料創新者和物流服務供應商之間競爭與合作的動態，正在塑造整合化、檢驗的解決方案和上市時間差異化優勢。

溫控藥品包裝領域的競爭格局呈現出多元化的特點，既有成熟的製造商，也有技術創新者和以物流為中心的服務供應商，各方透過夥伴關係和策略聯盟進行協作。現有包裝供應商專注於規模化生產、檢驗的設計方案和全球分銷網路，以幫助製造商獲得認證；而新參與企業則利用材料科學和物聯網技術的進步，推出更輕、可重複使用性更高、數據驅動的系統。隨著客戶對產品性能的持續需求以及對多段運輸路線可視性的日益重視，這些不同的策略正在逐漸整合。

透過數位化遙測、供應商多元化、循環系統實施和跨職能管治，為經營團隊提供加強低溫運輸韌性的實際可行的策略行動

產業領導者應採取一系列切實有效、影響深遠的措施，以增強低溫運輸韌性並獲得競爭優勢。首先，透過投資數位化遙測和持續監控能力，將間歇性檢驗轉變為持續保障。此類系統能夠降低風險，並為異常情況管理提供可操作的洞察。其次，實現關鍵隔熱材料和主動冷卻組件供應商的多元化，以降低受貿易政策波動和單一供應來源中斷的影響。最後，建立預先認證的替代設計方案，以便在需要時快速替換。

一項結合相關人員訪談、技術審查、情境分析和實驗室通訊協定評估的深入混合方法研究途徑，確保了研究結果的嚴謹性和可操作性。

本分析的調查方法結合了定性和定量方法，旨在得出可靠且實用的結論。主要研究工作包括對各類相關人員進行結構化訪談，例如包裝工程師、品質保證經理、物流負責人和採購主管，以獲取有關營運限制、檢驗方法和供應商選擇標準的第一手資料。此外，還對包裝規格、測試報告和案例研究進行了技術審查，以展示包裝在各種運輸條件下的運作性能。

將策略要求整合起來，強調檢驗的績效、持續監控、供應商柔軟性和生命週期思維，以此作為差異化優勢。

總之，溫控包裝是一項至關重要的策略能力，需要材料科學、物流設計、監管策略和商業規劃等多面向進行整合思考。在複雜生物製藥和疫苗需求的推動下，該領域正經歷快速創新。同時，2025年的政策變化和關稅趨勢凸顯了供應鏈敏捷性和供應商多元化的重要性。採用多層次細分方法進行包裝決策——綜合評估包裝類型、溫度範圍、應用、最終用戶需求、運輸方式和隔熱材料——能夠幫助企業客製化既能保護產品完整性又能符合實際營運需求的解決方案。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依包裝類型分類的藥品溫控包裝市場

  • 活性包裝
    • 電冷卻器
    • 相變材料
    • 冷凍機組
  • 被動式封裝
    • 乾冰
    • 發泡隔熱材料
    • 凝膠包

9. 依溫度範圍分類的藥品溫控包裝市場

  • 管制室溫
  • 冷凍
  • 冷藏

第10章：以運輸方式分類的藥品溫控包裝市場

  • 航空郵件
  • 陸運
  • 海運

第11章：以隔熱材料分類的醫藥溫控包裝市場

  • 發泡聚苯乙烯
  • 凝膠包插入物
  • 聚氨酯泡棉
  • 真空絕熱板

第12章：按應用分類的醫藥溫控包裝市場

  • 生物製藥
    • 單株抗體
    • 重組蛋白
  • 胰島素
  • 無菌注射劑
  • 疫苗
    • mRNA疫苗
    • 蛋白質次單元疫苗
    • 病毒載體疫苗

第13章：依最終用戶分類的藥品溫控包裝市場

  • 合約研究機構
  • 醫療機構
  • 物流運營商
  • 製藥公司

第14章：按地區分類的藥品溫控包裝市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：依組別分類的藥品溫控包裝市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國藥品溫控包裝市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國藥品溫控包裝市場

第18章：中國醫藥溫控包裝市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Air Liquide SA
  • Cold Chain Technologies, LLC
  • Cryopak Industries Inc.
  • Cryoport, Inc
  • Envirotainer AB
  • Pelican Products, Inc
  • Sealed Air Corporation
  • Softbox Solutions Ltd
  • Sonoco Products Company
  • Thermo Fisher Scientific Inc.
  • Va-Q-tec AG
  • World Courier, Inc.
Product Code: MRR-4F7A6D4FF2FA

The Temperature Controlled Package for Pharmaceutical Market was valued at USD 4.20 billion in 2025 and is projected to grow to USD 4.37 billion in 2026, with a CAGR of 5.23%, reaching USD 6.00 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.20 billion
Estimated Year [2026] USD 4.37 billion
Forecast Year [2032] USD 6.00 billion
CAGR (%) 5.23%

Comprehensive orientation to temperature controlled packaging articulating the strategic role of thermal integrity, traceability, and operational fit across pharmaceutical supply chains

The pharmaceutical cold chain has emerged as a defining element of modern healthcare logistics, driven by the proliferation of complex biologics and temperature-sensitive therapies. The integrity of temperature controlled packaging is no longer a back-office concern; it is a strategic enabler that preserves product efficacy, underpins regulatory compliance, and protects commercial value throughout global distribution networks. This introduction frames the market context by outlining the technical, operational, and regulatory forces shaping packaging selection, qualification, and deployment.

Advances in life sciences have increased the volume and variety of products that require precise thermal management during storage and transit. Concomitantly, logistics networks are adapting to handle shorter lead times, multi-modal movements, and geographically dispersed manufacturing footprints. These dynamics compel stakeholders to rethink traditional packaging paradigms and to invest in solutions that deliver repeatable temperature control, traceability, and validated performance across the entire journey from factory to patient.

Consequently, organizations must evaluate packaging through a multidimensional lens: thermal performance under real-world transit stress, compatibility with payloads such as monoclonal antibodies and mRNA vaccines, operational fit with air, ground, and ocean transport, and sustainability profiles that reflect growing environmental scrutiny. This introduction sets the stage for a deeper examination of transformative shifts, tariff impacts, segmentation intelligence, regional variation, supplier dynamics, and practical recommendations for industry leaders.

How digitalization, hybrid thermal technologies, sustainability imperatives, and heightened validation standards are redefining pharmaceutical cold chain packaging choices

The landscape for temperature controlled pharmaceutical packaging is undergoing transformative shifts that are reshaping procurement, engineering, and regulatory approaches. Digitalization and connected sensors now enable continuous temperature and shock monitoring, moving qualification from batch-based spot checks to continuous verification models that materially reduce risk. At the same time, the convergence of active and passive technologies provides hybrid solutions that combine phase change materials with electronically controlled cooling to meet increasingly narrow thermal envelopes demanded by advanced biologics.

Sustainability considerations are also prompting material innovation and lifecycle thinking. Insulation technologies such as vacuum insulated panels and advanced polyurethane alternatives are being evaluated not only for thermal efficiency but also for recyclability and end-of-life impact. These forces are further accentuated by operational changes: last-mile delivery complexities require modular, reusable packaging systems that can be integrated with cold storage hubs or micro-fulfillment centers, while expanded use of air freight for time-critical shipments favors lightweight, high-performance systems.

Regulatory rigor and validation expectations have intensified, driving standardized protocols for thermal performance and increasing demand for third-party test evidence. Taken together, these shifts require multidisciplinary responses that combine material science, data analytics, logistics design, and regulatory expertise to maintain product quality and manage total cost of ownership over repeated use cycles.

Assessing the combined operational and procurement consequences of 2025 United States tariff changes and their effects on supply resilience and packaging strategy adaptation

Policy changes and tariff measures in the United States in 2025 have exerted cumulative effects across global supply chains, influencing sourcing strategies, modal selection, and packaging economics. Tariff-driven cost pressures have encouraged many stakeholders to reassess supplier footprints and to accelerate diversification away from single-source overseas manufacturing for critical packaging components. This reorientation has downstream implications for lead times, qualification requirements, and inventory strategies as organizations seek resilient options that preserve quality while managing cost volatility.

Tariff impacts have also altered modal calculus, with some shippers favoring modes that reduce exposure to tariff-sensitive transits or that allow consolidation strategies to absorb incremental costs. Consequently, packaging requirements are evolving to support longer transit durations or to enable protective buffering when routing changes extend in-transit time. Procurement teams are increasingly focused on total landed cost considerations that include tariff exposure, customs handling, and potential rework or requalification costs tied to component substitutions.

At the same time, tariff uncertainty has catalyzed closer collaboration between packaging manufacturers, logistics providers, and pharmaceutical customers to design flexible supply arrangements. These arrangements often involve localized manufacturing of critical insulation components, strategic inventory hubs positioned to minimize tariff impacts, and contractual clauses that share the burden of sudden policy shifts. While tariffs add complexity, they also incentivize investments in agility, regionalized sourcing, and validated alternative materials and designs that can be deployed rapidly if trade conditions change.

Holistic segmentation analysis revealing how packaging type, temperature profile, application use case, end-user requirements, shipping mode, and insulation selection drive differentiated strategies

Effective segmentation analysis illuminates where innovation and investment will yield the greatest returns, and this market should be understood through multiple intersecting lenses. Based on Packaging Type, the market divides into Active Packaging and Passive Packaging, with Active solutions including electric coolers, phase change materials, and refrigeration units and Passive solutions encompassing dry ice, foam insulation, and gel packs; each choice carries different validation, energy, and reuse profiles that influence selection for a given payload. Based on Temperature Range, distinctions among controlled ambient, frozen, and refrigerated shipments dictate thermal performance criteria, qualification timelines, and monitoring expectations that must align with payload stability requirements.

Further granularity is provided by Application segmentation, where biologics, insulin, sterile injectables, and vaccines present distinct handling protocols and regulatory scrutiny. Within biologics, monoclonal antibodies and recombinant proteins often require narrow temperature control and gentle handling, while vaccine categories such as mRNA vaccines, protein subunit vaccines, and viral vector vaccines each impose unique cold chain demands that affect both packaging architecture and monitoring strategies. Based on End User, contract research organizations, healthcare facilities, logistics providers, and pharmaceutical manufacturers exercise different priorities: CROs emphasize sample integrity and traceability, healthcare facilities prioritize last-mile simplicity, logistics providers focus on durability and return logistics, and manufacturers seek validated scalability.

Considerations around Shipping Mode, including air freight, ground transportation, and sea freight, influence container design, shock resistance, and insulation thickness, while choices of Insulation Material - expanded polystyrene, gel pack inserts, polyurethane foam, and vacuum insulated panels - reflect tradeoffs between thermal efficiency, weight, cost, and sustainability. When these segmentation layers are overlaid, it becomes evident that optimal packaging strategies are highly contextual, requiring cross-functional evaluation of payload sensitivity, transit profile, regulatory constraints, and total lifecycle implications.

Regional differentiation and market dynamics across the Americas, Europe Middle East and Africa, and Asia Pacific that influence packaging selection, validation priorities, and distribution models

Regional dynamics shape how temperature controlled packaging is specified, procured, and operated, with geographic differences manifesting in regulatory frameworks, infrastructure maturity, and logistics networks. In the Americas, advanced cold chain infrastructure and high demand for biologics and specialty therapies drive the adoption of sophisticated active systems and integrated monitoring solutions, while regional hubs serve as centers for qualification testing and innovation. Cross-border trade within the hemisphere also influences inventory placement and distribution models, prompting multinational firms to calibrate packaging strategies to both regulatory expectations and commercial flows.

Europe, Middle East & Africa presents a mosaic of regulatory regimes and infrastructure capabilities. Western European markets often lead on sustainability requirements and advanced validation standards, encouraging investment in reusable systems and higher-efficiency insulation. In contrast, emerging markets within the region may place a premium on robustness and simplicity to manage variable transit conditions and intermittent cold storage availability. Consequently, packaging solutions that support modular validation and adaptable thermal performance can bridge performance expectations across disparate operating contexts.

Asia-Pacific exhibits rapid growth in pharmaceutical manufacturing and export activity, which elevates demand for packaging solutions that support long-haul air and sea shipments and that integrate with regional aggregation facilities. The region's supply base is also a source of material and component innovation, but differences in standards and testing practices require careful alignment to importing-market qualification requirements. Across all regions, local regulatory engagement, infrastructure assessment, and close collaboration with regional logistics partners are essential to ensure reliable cold chain performance.

Competitive and collaborative dynamics among established manufacturers, material innovators, and logistics service providers shaping integrated validated solutions and go-to-market differentiation

The competitive landscape in temperature controlled pharmaceutical packaging is characterized by a mix of established manufacturers, technology innovators, and logistics-centric service providers that are increasingly cooperating through partnerships and strategic alliances. Established packaging vendors focus on scale, validated designs, and global distribution networks that support manufacturer qualification, while newer entrants leverage materials science advances and IoT capabilities to introduce lighter, more reusable, and data-driven systems. These divergent approaches are converging as customers demand both proven performance and enhanced visibility across multi-leg journeys.

Service differentiation is emerging around end-to-end offerings where companies combine packaging hardware with monitoring-as-a-service, reverse logistics, and validation support, enabling customers to outsource complex qualification and operational responsibilities. Strategic collaborations between packaging suppliers and third-party logistics providers are producing turnkey solutions tailored for specific applications such as high-value biologics or temperature-critical vaccine distribution. Meanwhile, partnerships with research institutions and standards bodies accelerate the development of test protocols and cross-industry validation frameworks that reduce time-to-adoption for new materials and designs.

Investment patterns indicate a focus on modularity and scalability, with firms prioritizing assets that can be rapidly reconfigured for different payload classes and transport modes. Intellectual property around phase change formulations, vacuum panel construction, and sensor integration differentiates suppliers, but commercial success increasingly depends on service reliability, validated performance history, and the ability to support complex regulatory submissions for pharmaceutical customers.

Practical strategic actions for executives to strengthen cold chain resilience through digital telemetry, supplier diversification, circularity pilots, and cross-functional governance

Industry leaders should pursue a set of pragmatic, high-impact actions to strengthen cold chain resilience and capture competitive advantage. First, invest in digital telemetry and continuous monitoring capabilities to transition from episodic validation to continuous assurance; such systems reduce risk and provide actionable insights for exception management. Second, diversify supplier bases for critical insulation materials and active cooling components to mitigate exposure to trade policy shocks and single-source disruptions, and establish prequalified alternative designs to expedite substitution when necessary.

Third, prioritize lifecycle assessments and circularity in packaging selection by piloting reusable systems where return logistics are feasible and by evaluating the tradeoffs between single-use simplicity and reusable system economics. Fourth, align packaging qualification protocols with regulatory expectations early in the product development cycle, integrating real-world transit simulation and laboratory validation to avoid costly rework. Fifth, build cross-functional governance that brings procurement, quality, engineering, and logistics into a joint decision-making process so that thermal performance, cost, and operational feasibility are considered holistically.

Finally, engage proactively with regional logistics partners and regulatory stakeholders to shape standards and accelerate mutual recognition of validation evidence. Establishing collaborative pilots with carriers and healthcare providers can demonstrate reliability in last-mile contexts and support scalable rollouts. These recommendations emphasize pragmatic investment, governance, and partnerships as the foundation for maintaining product integrity while managing commercial imperatives.

Detailed mixed-methods research approach combining stakeholder interviews, technical review, scenario analysis, and laboratory protocol assessment to ensure rigorous actionable findings

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure robust, actionable conclusions. Primary research involved structured interviews with a cross-section of stakeholders including packaging engineers, quality assurance leaders, logistics operators, and procurement executives, providing firsthand insights into operational constraints, validation practices, and vendor selection criteria. These interviews were complemented by technical reviews of packaging specifications, test reports, and case studies that illustrate real-world performance under varied transit conditions.

Secondary research encompassed a systematic review of peer-reviewed literature, regulatory guidance documents, and industry white papers that inform current best practices in thermal management and cold chain validation. Where appropriate, laboratory test protocols and performance standards were referenced to evaluate insulation materials, phase change formulations, and active cooling units. Data triangulation techniques were applied to reconcile differing perspectives and to validate recurring themes across sources.

Analytical methods included scenario analysis to probe the effects of tariff shifts, modal changes, and product mix evolution, as well as sensitivity testing of operational assumptions such as transit duration and return logistics feasibility. Limitations of the study are clearly documented, including areas where emerging technologies require longer-term field validation, and the report highlights opportunities for targeted follow-up research to close evidence gaps and validate pilot deployments.

Synthesis of strategic imperatives highlighting validated performance, continuous monitoring, supplier flexibility, and lifecycle thinking as differentiators for cold chain success

In conclusion, temperature controlled packaging is a critical strategic capability that requires integrated thinking across materials science, logistics design, regulatory strategy, and commercial planning. The sector is experiencing rapid innovation driven by the needs of complex biologics and vaccines, while policy shifts and tariff dynamics in 2025 have underscored the importance of supply chain agility and supplier diversification. By approaching packaging decisions through layered segmentation - evaluating packaging type, temperature range, application, end-user needs, shipping mode, and insulation materials in combination - organizations can tailor solutions that protect product integrity and align with operational realities.

Looking forward, firms that combine validated technical performance with robust monitoring, flexible sourcing, and sustainability-minded lifecycle planning will be best positioned to manage uncertainty and protect patient outcomes. Cross-industry collaboration, early regulatory engagement, and investment in continuous assurance capabilities will further accelerate adoption of higher-performing systems. Ultimately, thoughtful packaging strategy is not merely a cost center but a differentiator that preserves therapeutic value, reduces clinical risk, and supports reliable access to temperature-sensitive medicines across global markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Temperature Controlled Package for Pharmaceutical Market, by Packaging Type

  • 8.1. Active Packaging
    • 8.1.1. Electric Coolers
    • 8.1.2. Phase Change Materials
    • 8.1.3. Refrigeration Units
  • 8.2. Passive Packaging
    • 8.2.1. Dry Ice
    • 8.2.2. Foam Insulation
    • 8.2.3. Gel Packs

9. Temperature Controlled Package for Pharmaceutical Market, by Temperature Range

  • 9.1. Controlled Ambient
  • 9.2. Frozen
  • 9.3. Refrigerated

10. Temperature Controlled Package for Pharmaceutical Market, by Shipping Mode

  • 10.1. Air Freight
  • 10.2. Ground Transportation
  • 10.3. Sea Freight

11. Temperature Controlled Package for Pharmaceutical Market, by Insulation Material

  • 11.1. Expanded Polystyrene
  • 11.2. Gel Pack Inserts
  • 11.3. Polyurethane Foam
  • 11.4. Vacuum Insulated Panels

12. Temperature Controlled Package for Pharmaceutical Market, by Application

  • 12.1. Biologics
    • 12.1.1. Monoclonal Antibodies
    • 12.1.2. Recombinant Proteins
  • 12.2. Insulin
  • 12.3. Sterile Injectables
  • 12.4. Vaccines
    • 12.4.1. Mrna Vaccines
    • 12.4.2. Protein Subunit Vaccines
    • 12.4.3. Viral Vector Vaccines

13. Temperature Controlled Package for Pharmaceutical Market, by End User

  • 13.1. Contract Research Organizations
  • 13.2. Healthcare Facilities
  • 13.3. Logistics Providers
  • 13.4. Pharmaceutical Manufacturers

14. Temperature Controlled Package for Pharmaceutical Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Temperature Controlled Package for Pharmaceutical Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Temperature Controlled Package for Pharmaceutical Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Temperature Controlled Package for Pharmaceutical Market

18. China Temperature Controlled Package for Pharmaceutical Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Air Liquide S.A.
  • 19.6. Cold Chain Technologies, LLC
  • 19.7. Cryopak Industries Inc.
  • 19.8. Cryoport, Inc
  • 19.9. Envirotainer AB
  • 19.10. Pelican Products, Inc
  • 19.11. Sealed Air Corporation
  • 19.12. Softbox Solutions Ltd
  • 19.13. Sonoco Products Company
  • 19.14. Thermo Fisher Scientific Inc.
  • 19.15. Va-Q-tec AG
  • 19.16. World Courier, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ELECTRIC COOLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ELECTRIC COOLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ELECTRIC COOLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHASE CHANGE MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHASE CHANGE MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHASE CHANGE MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATION UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATION UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATION UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY DRY ICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY DRY ICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY DRY ICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FOAM INSULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FOAM INSULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FOAM INSULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTROLLED AMBIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTROLLED AMBIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTROLLED AMBIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FROZEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FROZEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY AIR FREIGHT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY AIR FREIGHT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY AIR FREIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUND TRANSPORTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUND TRANSPORTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUND TRANSPORTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SEA FREIGHT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SEA FREIGHT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SEA FREIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY EXPANDED POLYSTYRENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY EXPANDED POLYSTYRENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY EXPANDED POLYSTYRENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACK INSERTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACK INSERTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACK INSERTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY POLYURETHANE FOAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY POLYURETHANE FOAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY POLYURETHANE FOAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACUUM INSULATED PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACUUM INSULATED PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACUUM INSULATED PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY LOGISTICS PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY LOGISTICS PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY LOGISTICS PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 209. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 210. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 216. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 242. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 243. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. NATO TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 253. NATO TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKE